Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems

Leukemia volume 14, pages 347–355 (2000)Cite this article

Abstract

DNA sequences which are complementary or ‘antisense’ to a target mRNA can inhibit expression of that mRNA's protein product. Antisense therapeutics has therefore received attention for inhibiting oncogenes in haematological malignancy, in particular in chronic myeloid leukaemia. However, it is now becoming clear that antisense therapeutics is considerably more problematic than was naively initially assumed. In this article, some of these difficulties are discussed, together with the achievements in CML so far. Considerable further research is required in order to define an optimal antisense therapeutics strategy for clinical use.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Nienhuis AW . Genetic mechanisms in neoplasia Blood 1984 64: 949–950

    CAS  PubMed  Google Scholar 

  2. Anderson WF . Human gene therapy Nature 1998 392: 25–30

    CAS  PubMed  Google Scholar 

  3. Verma IM, Somia N . Gene therapy–promises, problems and prospects Nature 1997 389: 239–242

    CAS  PubMed  Google Scholar 

  4. Gewirtz AM, Sokol DL, Ratajczak MZ . Nucleic acid therapeutics: state of the art and future prospects Blood 1998 92: 712–736

    CAS  PubMed  Google Scholar 

  5. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F . Clinical application of ribozymes Lancet 1995 345: 1027–1031

    CAS  PubMed  Google Scholar 

  6. James HA, Gibson I . The therapeutic potential of ribozymes Blood 1998 91: 371–382

    CAS  PubMed  Google Scholar 

  7. Zamecnik PC, Stephenson ML . Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide Proc Natl Acad Sci USA 1978 75: 280–284

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Stein CA, Cheng YC . Antisense oligonucleotides as therapeutic agents–is the bullet really magical? Science 1993 261: 1004–1012

    CAS  PubMed  Google Scholar 

  9. Khan IM, Coulson JM . A novel method to stabilise antisense oligonucleotides against exonuclease degradation (published erratum appears in Nucleic Acids Research 21: 4433, 1993) Nucleic Acids Res 1993 21: 2957–2958

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Giles RV, Spiller DG, Tidd DM . Chimaeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity Anti-Cancer Drug Design 1993 8: 33–51

    CAS  PubMed  Google Scholar 

  11. Giles RV, Spiller DG, Green JA, Clark RE, Tidd DM . Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA Blood 1995 86: 744–754

    CAS  PubMed  Google Scholar 

  12. Wilkinson YA, McKenna PG . The effects of thymidine on deoxyribonucleotide pool level, cytotoxicity and mutation induction in Friend mouse erythroleukaemia cells Leukemia Res 1989 13: 615–620

    CAS  Google Scholar 

  13. Tanaka Y, Yoshihara K, Tsuyuki M, Kamiya T . Apoptosis induced by adenosine in human leukaemia HL-60 cells Exp Cell Res 1994 213: 242–252

    CAS  PubMed  Google Scholar 

  14. Ross DD, Akman SA, Schrecker AW, Bachur NR . Effects of deoxynucleosides on cultured human leukaemia cell growth and deoxynucleotide pools Cancer Res 1981 41: 4493–4498

    CAS  PubMed  Google Scholar 

  15. Russell NH, Hoffbrand AV, Bellingham AJ . Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow Leukemia Res 1986 10: 325–329

    CAS  Google Scholar 

  16. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P . BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but non-antisense mechanism Blood 1995 86: 3891–3896

    CAS  PubMed  Google Scholar 

  17. Vaerman JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F, Martiat P . Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides Blood 1997 90: 331–339

    CAS  PubMed  Google Scholar 

  18. Vaerman JL, Martiat P . How do antisense oligdeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Blood 1996 87: 4020

    CAS  Google Scholar 

  19. Gao WY, Storm C, Egan W, Cheng YC . Cellular pharmacology of phosphorthioate homooligodeoxynucleotides in human cells Mol Pharmacol 1993 43: 45–50

    CAS  PubMed  Google Scholar 

  20. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L . Aptameric inhibition of p210 BCR-ABL tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure Nucleic Acids Res 1994 22: 2150–2154

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Bergan R, Kyle E, Connell Y, Neckers L . Inhibition of protein tyrosine kinase activity in intact cells by the aptameric action of oligodeoxyribonucleotides Antisense Res Dev 1995 5: 33–38

    CAS  PubMed  Google Scholar 

  22. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM . Antisense bcr-abl oligomers cause non-specific inhibition of chronic myeloid leukaemia cell lines Leukemia 1994 8: 2156–2162

    CAS  PubMed  Google Scholar 

  23. Miller PS, McParland KB, Jayaraman K, Ts'o POP . Biochemical and biological effects of nonionic nucleic acid methylphosphonates Biochemistry 1981 20: 1874–1880

    CAS  PubMed  Google Scholar 

  24. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G . Liposomal delivery of methylphosphonate antisense oligonucleotides in chronic myelogenous leukemia Blood 1994 84: 601–607

    CAS  PubMed  Google Scholar 

  25. Tidd DM, Hawley P, Warenius HM, Gibson I . Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues Anti-Cancer Drug Design 1988 3: 117–127

    CAS  PubMed  Google Scholar 

  26. Smetsers TFCM, Linders EHP, van de Locht LTF, de Witte TM, Mensink EJBM . An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism Br J Haematol 1997 96: 377–381

    CAS  PubMed  Google Scholar 

  27. Giles RV, Spiller DG, Grzybowski J, Clark RE, Nicklin P, Tidd DM . Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells Nucleic Acids Res 1998 26: 1567–1575

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Giles RV, Tidd DM . Enhanced RNase H activity with methylphosphonodiester phosphodiester chimaeric antisense oligodeoxynucleotides Anti-Cancer Drug Design 1992 7: 37–48

    CAS  PubMed  Google Scholar 

  29. Yaswen P, Stampfer M, Ghosh K, Cohen J . Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells Antisense Res Dev 1993 3: 67–77

    CAS  PubMed  Google Scholar 

  30. Burgess TL, Fischer EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL . The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism Proc Natl Acad Sci USA 1995 92: 4051–4055

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Yamamato S, Yamamato T, Kataoka T, Kuramoto E, Yano O, Tokunaga T . Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment IFN-mediated natural killer activity J Immunol 1992 148: 4072–4076

    Google Scholar 

  32. Krieg AM, Matson S, Fisher E . Oligodeoxynucleotide modifications determine the magnitude of B-cell stimulation by CpG motifs Antisense Nucleic Acid Drug Dev 1996 6: 133–139

    CAS  PubMed  Google Scholar 

  33. Stacey KJ, Sweet MJ, Hume DA . Macrophages ingest and are activated by bacterial DNA J Immunol 1996 157: 2116–2122

    CAS  PubMed  Google Scholar 

  34. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ . Immunostimulatory oligodeoxyribonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma Blood 1997 89: 2994–2998

    CAS  PubMed  Google Scholar 

  35. Tidd DM, Spiller DG, Broughton CM, Clark RE, Giles RV . Oligodeoxynucleotides with a CpG motif induce apoptosis in T lymphocytic leukemia lines. (Submitted)

  36. Giles RV, Grzybowski J, Spiller DG, Tidd DM . Enhanced antisense effects resulting from an improved Streptolysin O protocol for oligodeoxynucleotide delivery into human leukaemia cells Nucleotides Nucleosides 1997 16: 1155–1163

    CAS  Google Scholar 

  37. Spiller DG, Giles RV, Broughton CM, Grzybowski J, Ruddell CJ, Tidd DM, Clark RE . The influence of target protein half-life on the effectiveness of antisense oligonucleotide analogue mediated biological responses Antisense Res Dev 1998 8: 281–293

    CAS  Google Scholar 

  38. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL . Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages Nucleic Acids Res 1991 19: 5543–5550

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Tonkinson JL, Stein CA . Patterns of intracellular compartmentalisation, trafficking and acidification of 5′-fluorescein labelled phosphodiester and phosphorothioate oligodeoxyribonucleotides in HL60 cells Nucleic Acids Res 1994 22: 4268–4275

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Moller P, Johnsen HE, Dahl O . Stability and cellular uptake of phosphorothioate oligodeoxyribonucleotides (PS-ODNs) in human stem cells Bone Marrow Transplant 1995 15: (Suppl. 2) S107 (Abstr.)

    Google Scholar 

  41. Agrawal S, Temsamini J, Tang JY . Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice Proc Natl Acad Sci USA 1991 88: 7595–7599

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA . Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells Biochemistry 1993 32: 4855–4861

    CAS  PubMed  Google Scholar 

  43. Spiller DG, Tidd DM . The uptake kinetics of chimaeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells Anticancer Drug Design 1992 7: 115–129

    CAS  Google Scholar 

  44. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML . DNA mediated immunisation in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state Proc Natl Acad Sci USA 1996 93: 12496–12501

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Noonberg SB, Garovoy MR, Hunt CA . Characteristics of oligonucleotide uptake in human keratinocyte cultures J Invest Dermatol 1993 101: 727–731

    CAS  PubMed  Google Scholar 

  46. Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ . Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes J Invest Dermatol 1994 103: 569–575

    CAS  PubMed  Google Scholar 

  47. Clark RE . Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia Leuk Lymphoma 1995 19: 189–195

    CAS  PubMed  Google Scholar 

  48. Bennett CF, Chiang M-Y, Chan H, Shoemaker JE, Mirabelli CK . Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides Mol Pharmacol 1992 41: 1023–1033

    CAS  PubMed  Google Scholar 

  49. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C . Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation EMBO J 1991 10: 1111–1118

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Boutorin AS, Gus'kova LV, Ivanova EM, Kobetz ND, Zarytova VF, Ryte AS, Yurchenko LV, Vlassov VV . Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazium residues at their 3′-terminus and their interaction with DNA within mammalian cells FEBS Lett 1989 254: 129–132

    CAS  PubMed  Google Scholar 

  51. Leonetti J-P, Degols G, Lebleu B . Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake Bioconj Chem 1990 1: 149–153

    CAS  Google Scholar 

  52. Spiller DG, Giles RV, Grzybowski J, Tidd DM, Clark RE . Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukaemia cells: a comparison of Streptolysin-O permeabilisation, electroporation and lipophilic conjugation Blood 1998 91: 4738–4746

    CAS  PubMed  Google Scholar 

  53. Thierry AR, Rahman A, Dritschilo A . Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides Biochem Biophys Res Commun 1993 190: 952–960

    CAS  PubMed  Google Scholar 

  54. Ropert C, Lavignon M, Dubemet C, Couvreur P, Malvy C . Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus Biochem Biophys Res Commun 1992 183: 879–885

    CAS  PubMed  Google Scholar 

  55. Clarenc JP, Degols G, Leonetti JP, Milhaud P, LeBleu B . Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation Anticancer Drug Design 1993 8: 81–94

    CAS  Google Scholar 

  56. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C . Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides Pharma Res 1992 9: 441–449

    CAS  Google Scholar 

  57. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr J-P . A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proc Natl Acad Sci USA 1995 92: 7297–7301

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Colige A, Sokolov BP, Nugent P, Baserga R, Prockop DJ . Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells Biochemistry 1993 32: 7–11

    CAS  PubMed  Google Scholar 

  59. Konopleva M, Tari A, Lopez-Berenstein G, Andreef M . Inhibition of BCL-2 with liposomal-delivered antisense oligonucleotides (AS-ODN) induces apoptosis and increases the sensitivity of primary acute myeloid leukaemia (AML) cells and cell lines to cytosine arabinoside and doxorubicin Blood 1997 90: (Suppl. 1) 494a (Abstr.)

    Google Scholar 

  60. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L . Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging Blood 1996 88: 731–741

    CAS  PubMed  Google Scholar 

  61. Taj AS, Martiat P, Dhut S, Chaplin TL, Dowding C, Th'ng KH, Goldstein I, Daley GQ, Young BD, Goldman JM . Inhibition of p210 bcr-abl expression in K562 cells by electroporation with antisense oligonucleotides Leuk Lymphoma 1990 3: 201–208

    CAS  PubMed  Google Scholar 

  62. Etkin M, Filaccio M, Ellerson D, Suh S, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Moseley AM, Reading C, Khouri I, Talpaz M, Kantarjian H, Deisseroth A . Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukaemia patients and from normal individuals Hum Gene Ther 1992 3: 137–145

    CAS  PubMed  Google Scholar 

  63. Hughes PF, Thacker JD, Hogge D, Sutherland HJ, Thomas TE, Lansdorp PM, Eaves CJ, Humphries RK . Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures J Clin Invest 1992 89: 1817–1824

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Martiat P, Lewalle P, Taj AS, Phillipe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL . Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines Blood 1993 81: 502–509

    CAS  PubMed  Google Scholar 

  65. Cornetta K, Moore A, Leemhuis T, Moen RC, Tricot G, Leibowitz D, Hoffman R . Retroviral mediated gene transfer in chronic myelogenous leukaemia Br J Haematol 1994 87: 308–316

    CAS  PubMed  Google Scholar 

  66. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM . Single base discrimination for ribonuclease H dependent antisense effects within intact human leukaemia cells Nucleic Acids Res 1995 23: 954–961

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Spiller DG, Tidd DM . Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilisation of human leukaemia cells with streptolysin O Antisense Res Dev 1995 5: 13–21

    CAS  PubMed  Google Scholar 

  68. Broughton CM, Spiller DG, Pender N, Komorovskaya M, Grzybowski J, Giles RV, Tidd DM, Clark RE . Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients Leukemia 1997 11: 1435–1441

    CAS  PubMed  Google Scholar 

  69. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G . Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22 Cell 1984 36: 93–99

    CAS  PubMed  Google Scholar 

  70. Kurzrock R, Gutterman JU, Talpaz M . The molecular genetics of philadelphia chromosome-positive leukemias New Engl J Med 1988 319: 990–998

    CAS  PubMed  Google Scholar 

  71. Editorial . Chronic myeloid leukaemia: potential for antisense therapy Lancet 1992 340: 1262–1263

    Google Scholar 

  72. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B . Selective inhibition of leukaemia cell proliferation by bcr-abl antisense oligodeoxynucleotides Science 1991 253: 562–565

    CAS  PubMed  Google Scholar 

  73. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J . Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction Exp Hematol 1995 23: 1606–1611

    CAS  PubMed  Google Scholar 

  74. Smetsers TFCM, Skorski T, van de Locht LTF, Wessels HMC, Pennings AHM, De Witte T, Calabretta B, Mensink EJBM . Antisense bcr-abl oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173 Leukemia 1994 8: 129–140

    CAS  PubMed  Google Scholar 

  75. De Fabritiis P, Amadori S, Calabretta B, Mandelli F . Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides Bone Marrow Transplant 1993 12: 261–265

    CAS  PubMed  Google Scholar 

  76. De Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B . Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells Leukemia 1997 11: 811–819

    CAS  PubMed  Google Scholar 

  77. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG . BCR-ABL maintains resistance of chronic myelogenous leukaemia cells to apoptotic cell death Blood 1994 83: 1179–1187

    CAS  PubMed  Google Scholar 

  78. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ . Inhibition of apoptosis by BCR-ABL in chronic myeloid leukaemia Blood 1994 83: 2038–2044

    CAS  PubMed  Google Scholar 

  79. Smetsers TFCM, van de Locht LTF, Pennings AHM, Wessels HMC, de Witte TM, Mensink EJBM . Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular BCR-ABL protein levels Leukemia 1995 9: 118–130

    CAS  PubMed  Google Scholar 

  80. Dhut S, Chaplin T, Young BD . BCR-ABL and BCR proteins; biochemical characterisation and localisation Leukemia 1990 4: 745–750

    CAS  PubMed  Google Scholar 

  81. Croce CM, Nowell PC . Molecular basis of human B cell neoplasia Blood 1985 65: 1–7

    CAS  PubMed  Google Scholar 

  82. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo R, Croce CM . Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells Proc Natl Acad Sci USA 1982 79: 7824–7827

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada T, Finan J, Emanuel BS, Nowell PC, Croce CM . Deregulation of c-myc by translocation of the T-cell receptor in T-cell leukaemias Science 1986 232: 884–886

    CAS  PubMed  Google Scholar 

  84. Chang H, Benchimol S, Minden MD, Messner HA . Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma Blood 1994 83: 452–459

    CAS  PubMed  Google Scholar 

  85. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I . Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas Blood 1994 84: 883–888

    CAS  PubMed  Google Scholar 

  86. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE . Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders Blood 1995 85: 552–565

    CAS  PubMed  Google Scholar 

  87. Weisenburger DD, Armitage JO . Mantle cell lymphomal–an entity comes of age Blood 1996 87: 4483–4494

    CAS  PubMed  Google Scholar 

  88. Sawyers CL . Callahan W, Witte ON. Dominant negative myc blocks transformation by abl oncogenes Cell 1992 70: 901–910

    CAS  PubMed  Google Scholar 

  89. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL . Differential complementation of bcr-abl point mutants with c-myc Science 1994 264: 424–426

    CAS  PubMed  Google Scholar 

  90. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR . Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F Nature 1997 387: 422–426

    CAS  PubMed  Google Scholar 

  91. Land H, Parada LF, Weinberg RA . Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes Nature 1982 304: 596–602

    Google Scholar 

  92. Kohl NE, Ruley HE . Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes Oncogene 1987 2: 41–48

    CAS  PubMed  Google Scholar 

  93. Sanchez-Garcia I, Grutz G . Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL-2 Proc Natl Acad Sci USA 1995 92: 5287–5291

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Beimling P, Benter T, Sander T, Moelling K . Isolation and characterisation of the human cellular MYC gene product Biochemistry 1985 24: 6349–6355

    CAS  PubMed  Google Scholar 

  95. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E . Human promyelocytic leukaemia HL60 cell proliferation and c-MYC protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-MYC mRNA Proc Natl Acad Sci USA 1988 85: 1028–1032

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM . A c-MYC antisense oligodeoxyribonucleotide inhibits entry into S phase but not progression from G0 to G1 Nature 1987 328: 445–449

    CAS  PubMed  Google Scholar 

  97. Holt JT, Redner RL, Nienhuis AW . An oligomer complementary to c-MYC mRNA inhibits proliferation of HL60 promyelocytic cells and induces differentiation Mol Cell Biol 1988 8: 963–973

    CAS  PubMed  PubMed Central  Google Scholar 

  98. McManaway ME, Neckers LM, Loke SL, Al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, McGrath IT . Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide Lancet 1990 335: 808–811

    CAS  PubMed  Google Scholar 

  99. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN . Gene marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341: 85–86

    CAS  PubMed  Google Scholar 

  100. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C . Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML Blood 1994 83: 3068–3076

    CAS  PubMed  Google Scholar 

  101. Letheby BA, Jackson JD, Whalen VL, Bishop MR, Iversen PL, Sharp JG, Kessinger A, Armitage JO, Warkentin PI . Ex vivo treatment of normal peripheral blood-derived progenitor cells with antisense bcr-abl oligonucleotides Exp Hematol 1994 22: 778 (Abstr.)

    Google Scholar 

  102. Keating A, Wang XH, Laraya P . Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia Blood 1994 83: 1744–1749

    CAS  PubMed  Google Scholar 

  103. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, Jones RJ . BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia Blood 1993 81: 2898–2902

    CAS  PubMed  Google Scholar 

  104. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B . G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-MYB Science 1989 245: 180–183

    CAS  PubMed  Google Scholar 

  105. Oehler T, Arnold H, Biedenkapp H, Klempnauer KH . Characterization of the v-myb binding domain Nucleic Acids Res 1990 18: 1703–1710

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Weber BL, Westin EH, Clarke MF . Differentiation of mouse erythroleukaemia cell enhanced by alternatively spliced c-myb mRNA Science 1990 249: 1291–1293

    CAS  PubMed  Google Scholar 

  107. Mucenski ML, McLain K, Kier AB, Swerdlow AH, Schreiner CM, Miller TA, Peitryga DW, Scott WJ Jr, Potter SS . A functional c-myb gene is required for normal fetal hepatic hematopoiesis Cell 1991 65: 677–689

    CAS  PubMed  Google Scholar 

  108. Calabretta B, Sims RB, Valiteri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM . Normal and leukaemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-MYB antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging Proc Natl Acad Sci USA 1991 88: 2351–2355

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM . Acute and chronic phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-MYB antisense oligodeoxynucleotides Blood 1992 79: 1956–1961

    CAS  PubMed  Google Scholar 

  110. Gewirtz AM, Calabretta B . A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro Science 1988 242: 1303–1306

    CAS  PubMed  Google Scholar 

  111. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ . Oligodeoxynucleotide therapeutics for human myelogenous leukaemia: interim results Blood 1996 88: (Suppl. 1) 270a (Abstr.)

    Google Scholar 

  112. de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F . BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukaemia in advanced phase Blood 1998 91: 3156–3162

    CAS  PubMed  Google Scholar 

  113. Sun J, Zhou S, Wu B, Liu Q, Feng R, Liu X . Autologous bone marrow translantation after in vitro purging with BCR/ABL antisense for CML patients Exp Hematol 1997 25: 812 (Abstr.)

    Google Scholar 

  114. Clark RE, Grzybowski J, Broughton CM, Pender N, Spiller DG, Brammer C, Giles RV, Tidd DM . Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia Bone Marrow Transplant 1999 23: 1303–1308

    CAS  PubMed  Google Scholar 

  115. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B . Suppression of Philadelphial leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide Proc Natl Acad Sci USA 1994 91: 4504–4508

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B . Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukaemia blast crisis in SCID mice Blood 1996 88: 1005–1012

    CAS  PubMed  Google Scholar 

  117. Cotter FE, Johnson P, Hall P, Pocock C, al-Mahdi N, Cowell JK, Morgan G . Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model Oncogene 1994 9: 3049–3055

    CAS  PubMed  Google Scholar 

  118. Webb A, Cunningham D, Cotter F, Clarke PA, Di Stefano F, Ross P, Corbo M, Dziewanowska Z . BCL-2 antisense therapy in patients with non-Hodgkin lymphoma Lancet 1997 349: 1137–1141

    CAS  PubMed  Google Scholar 

  119. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A . Phase I trial of an antisense oligonucleotide OL(1)p53 in haematological malignancies J Clin Oncol 1996 14: 1320–1326

    CAS  PubMed  Google Scholar 

  120. Barton C, Lemoine N . Antisense oligonucleotides targeting p53 (Better) J Clin Oncol 1997 15: 408

    CAS  PubMed  Google Scholar 

  121. Agrawal S . Antisense oligonucleotides: towards clinical trials Trends Biotechnol 1996 14: 376–387

    CAS  PubMed  Google Scholar 

  122. Morgan R, Edge M, Colman A . A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligonucleotides Nucleic Acids Res 1993 21: 4615–4620

    CAS  PubMed  PubMed Central  Google Scholar 

  123. McKay RA, Cummins LL, Graham MJ, Lesnik EA, Owens SR, Winniman M, Dean NM . Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C by the incorporation of 2′-O-propyl modifications Nucleic Acids Res 1996 24: 411–417

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Altmann K-H, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, Nicklin P . Second-generation antisense oligonucleotides: structure–activity relationships and the design of improved signal-transduction inhibitors Biochem Soc Trans 1996 24: 630–636

    CAS  PubMed  Google Scholar 

  125. Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, Thomson SA, Pipe A, Hassman F, Bisi JE, Froehler BC, Matteucci MD, Wagner RW, Noble SA, Babiss LE . An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers Nucleic Acids Res 1995 23: 1197–1203

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Wagner RW . Gene inhibition using antisense oligodeoxynucleotides Nature 1994 372: 333–335

    CAS  PubMed  Google Scholar 

  127. Nielson PE, Egholm M, Berg RH, Buchardt O . Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide Science 1991 254: 1497–1500

    Google Scholar 

  128. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE . PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen bonding rules Nature 1993 365: 566–568

    CAS  PubMed  Google Scholar 

  129. Antivirals Technical Report No. 2 Antisense Research and Development 3: after p153 1993

  130. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD . Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation Antisense Nucleic Acid Drug Dev 1996 6: 267–272

    CAS  PubMed  Google Scholar 

  131. Giles RV, Spiller DG, Clark RE, Tidd DM . Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA Antisense Res Dev 1999 9: 213–220

    CAS  Google Scholar 

  132. Sierakowska H, Sambade MJ, Agrawal S, Kole R . Repair of thalassaemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides Proc Natl Acad Sci USA 1996 93: 12840–12844

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Kang SH, Cho MJ, Kole R . Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development Biochemistry 1998 37: 6235–6239

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Leukaemia Research Fund of Great Britain.

Author information

Authors and Affiliations

  1. University Department of Haematology, Royal Liverpool University Hospital, Prescot St, Liverpool, L7 8XP, UK

    RE Clark

Authors
  1. RE Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, R. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 14, 347–355 (2000). https://doi.org/10.1038/sj.leu.2401677

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401677

Keywords

This article is cited by

Search

Advanced search

Quick links